TrialPanorama/Dataset huggingface dataset:
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Computerized EMR-Assisted Smoking Cessation (CEASCE)
Brief Summary: RATIONALE: Computer-based stop smoking programs may assist doctors in helping patients stop smoking.

PURPOSE: This randomized clinical trial is studying how well a computer-based stop smoking program works in assisting doctors in helping adults stop smoking.


Options:
A: DISEASE CHARACTERISTICS:

* Enrolled in a participating Medicaid Managed Care Organization (MMCO) as a Medicaid patient for ≥ 12 months
* Not up-to-date (UTD) for colorectal cancer screening

  * UTD status defined by any of the following:

    * Home fecal occult blood test within the past 12 months
    * Flexible sigmoidoscopy within the past 5 years
    * Double-contrast barium enema within the past 5 years
    * Colonoscopy within the past 10 years
* Registered to receive primary care from a participating Community/Migrant Health Center, Diagnostic and Treatment Center, or other participating practice in New York City
* Must have a telephone available
* No MMCO claim for any of the following:

  * Colorectal, breast, or cervical cancer
  * Colon polyp removal
  * Total colectomy

PATIENT CHARACTERISTICS:

* Female
* Able to use telephone
* No plans to move for ≥ 1 year

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
B: Inclusion Criteria:

* hospitals participating in the ACTION Registry GWTG

Exclusion Criteria:

* sites with low volume of data submission (\< 10 data forms in the past year)
C: Inclusion Criteria:

* icd9 code for diabetes
* primary care visit in the past 18 months
* English or Spanish as primary language

Exclusion Criteria:

* age more than 75
* No working address
D: DISEASE CHARACTERISTICS:

* Primary care providers and their patients in the Brigham and Women's Primary Care Practice-Based Research Network
* Patient is currently a smoker

PATIENT CHARACTERISTICS:

* Must speak English or Spanish
* No significant cognitive impairment (e.g., dementia or active psychosis)

PRIOR CONCURRENT THERAPY:

* Not specified

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Computerized EMR-Assisted Smoking Cessation (CEASCE)
Brief Summary: RATIONALE: Computer-based stop smoking programs may assist doctors in helping patients stop smoking.

PURPOSE: This randomized clinical trial is studying how well a computer-based stop smoking program works in assisting doctors in helping adults stop smoking.


Options:
A: Inclusion Criteria:

* patient with suspected pulmonary embolism
* prescription of a specific paraclinical diagnostic investigation or start of a specific treatment for pulmonary embolism

Exclusion Criteria:

* confirmation or exclusion of pulmonary embolism before admission in emergency department
* confirmation of deep venous thrombosis before admission in emergency department
* suspicion of pulmonary embolism during hospitalization (in-patient)
* suspicion of pulmonary embolism without investigation realization
* patient already included in the study
* patient refusing the utilization of his data for the study
B: Inclusion Criteria:

* The subjects of this study will be physician providers and residents and medical students practicing under the supervision of a faculty emergency physician. Specific study subjects will include emergency medicine faculty physicians; emergency medicine and internal medicine residents; emergency medicine, surgery, and internal medicine interns; and medical students taking care of patients in our emergency department.

Exclusion Criteria:

* We will not include the members of the research team in this study.
C: DISEASE CHARACTERISTICS:

* Primary care providers and their patients in the Brigham and Women's Primary Care Practice-Based Research Network
* Patient is currently a smoker

PATIENT CHARACTERISTICS:

* Must speak English or Spanish
* No significant cognitive impairment (e.g., dementia or active psychosis)

PRIOR CONCURRENT THERAPY:

* Not specified
D: Inclusion Criteria:

* Primary care practice sites within the Geisinger Health System

Exclusion Criteria:

* Sites with \< 1000 visits per year for acute respiratory infection

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Trial of Vitamins in HIV Progression and Transmission (A Trial of Vitamins and HAART in HIV Disease Progression)
Brief Summary: This study is a double-blind randomized clinical trial, conducted to examine the effects of multivitamins (including B, C, and E) on HIV disease progression among HIV-positive Tanzanian adult men and women taking highly active anti-retroviral therapy (HAART).


Options:
A: Inclusion Criteria:

* HIV infected
* HIV-RNA \< 400 copies/ml at study entry and for 12 wks. prior
* 25-hydroxyvitamin D level \<20
* On a stable anti-retroviral (ARV) regimen for at least 12 weeks prior to study entry

Exclusion Criteria:

* Pregnancy or Breast Feeding
* Diabetes
* Creatinine Clearance \<50
* Any active infectious or inflammatory condition
* aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5 within 6 months prior to study entry
B: Inclusion Criteria:

* HIV-positive
* Men or Women
* 18 Years of Age or older
* Initiating HAART at time of randomization

Exclusion Criteria:

* Pregnant or Lactating Women
* Individuals at pre-HAART disease stages
* BMI less than 16
C: Inclusion Criteria:

* Men and women, age 18 to 60 years inclusive
* At least two positive sputum smears for tuberculosis
* Intention to stay in Dar-es-Salaam for at least 2 years after the start of TB therapy
* Subjects who grant informed consent to participation

Exclusion Criteria:

* Karnofsky score \< 40%
* Hemoglobin \< 8.5 g/dl
* Having had treatment for TB exceeding 4 weeks in the last 5 years
* Pregnant women
D: Inclusion Criteria:

* Age 18 years and 0 days through 24 years and 364 days
* HIV-1 infection as documented by any licensed ELISA test kit and confirmed by Western blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a method other than ELISA at any time prior to study entry
* Currently being treated with a stable FDA-approved ARV combination therapy, containing \> 3 antiretrovirals, for \> 28 days, according to HRSA guidelines. Treatment regimen will not be started or changed for the purposes of participation in this study. Subjects will be receiving therapy at the direction of their treating physician
* Willingness to remain on the same ARV combination therapy for the 12-week duration of the study
* Ability and willingness to participate in the study by providing written informed consent
* Willingness to be randomized to receive either vitamin D or placebo

Exclusion Criteria:

* Prior hypersensitivity to vitamin D
* History of arteriosclerosis, renal stones, glomerulonephritis, nephrotic syndrome, or hypercalcemia
* Lactation or current pregnancy
* Active therapy for malignancy
* Known presence of gastrointestinal disease that would interfere with drug administration or absorption
* Serological evidence of Hepatitis B surface antigen (HBsAg)
* Confirmed creatinine clearance \< 90 ml/min (calculated GFR from serum creatinine using the MDRD formula)
* Grade 3 or higher clinical toxicity

Answer: B
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Home-Based Tele-Health Stroke Care: A Randomized Trial for Veterans
Brief Summary: The purpose of the proposed study is to examine a Tele-rehabilitation (TR) intervention that uses tele-health technology to improve outcomes of stroke patients after discharge to home. The primary aim is to determine the effect of TR on physical function, and secondarily to determine the effect on disability, falls-related self-efficacy, and patient satisfaction.


Options:
A: Inclusion Criteria:

* Suspected stroke or TIA within 24 hours from symptom onset

Exclusion Criteria:

* MRI contraindication
B: Inclusion Criteria:

* Patients with chronic obstructive pulmonary disease stage II-III (GOLD classification)

Exclusion Criteria:

* Cognitive impairment precluding the use of the experimental device.
C: DISEASE CHARACTERISTICS:

* Diagnosis of cancer AND 1 or both of the following:

  * Clinical depression

    * Depression must be of at least moderate severity (PHQ-9 score ≥ 10)

      * Depressed mood and/or anhedonia endorsed
    * No depression directly precipitated by cancer therapy for which depression is a well known side effect (e.g., interferon, corticosteroids)
  * Cancer-related pain

    * Pain must be at least moderate in severity (Brief Pain Inventory score ≥ 6), persisted despite using ≥ 2 analgesics, and cancer-related
    * If the only pain is due to a pre-existing condition (e.g., migraine, headache, arthritis, etc), the patient may not be eligible

PATIENT CHARACTERISTICS:

* Life expectancy ≥ 6 months
* Must speak English
* Not pregnant
* Fertile patients must use effective contraception
* No moderately severe cognitive impairment
* No schizophrenia or other psychosis
* No disability claim currently being adjudicated for pain

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* Not in hospice care
D: Inclusion Criteria:

* Have acute ischemic or hemorrhagic stroke within the preceding twenty-four months, defined as "a rapid onset event of vascular origin reflecting a focal disturbance of cerebral function, excluding isolated impairments of higher function and persisting longer than 24 hours";
* age between 45-90;
* discharge to the community;
* cognitively intact (score of 6/10 or greater on the Short Portable Mental Status Questionnaire);
* discharge motor Functional Independence Measure (FIM) score of 17-88 (i.e., maximal assistance on no more than 4 motor activities of daily living (ADLs) as the most severe stroke included and modified independence at least 2 motor ADLs as the least severe); able to follow 3-step command; signed VHA Medical Media release form; concurrence by the patient's physician;
* and informed consent

Exclusion Criteria:

Unable to provide informed consent

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Computer-assisted Screening for Intimate Partner Violence in Family Practice - a Randomized Controlled Trial
Brief Summary: This study tested the effectiveness of computer-assisted screening for identifying patients at risk of intimate partner violence (IPV) in a Canadian family practice. It was hypothesized that the use of computer-assisted screening among female patients would lead to higher rates of IPV discussion-opportunity and IPV detection during medical consultations, compared to patients receiving standard medical care.


Options:
A: Inclusion Criteria:

* women attending obstetrics \& gynecology (OB-GYN), family planning, general medicine, family medicine or HIV/Sexually transmitted disease (STD) clinic

Exclusion Criteria:

* non-English speaking other than Spanish speakers
* accompanied by a child \>3 years of age without adequate provision for child care;
* Visually- or hearing-impaired women;
* without access to a telephone;
* Severe Mental impairment
B: Inclusion Criteria:

* Older than 18 or an emancipated minor

Exclusion Criteria:

* Child undergoing acute resuscitation
* Other adults in the room
C: Inclusion Criteria:

* African American or Latina (by self report)
* At least 18 years of age
* English speaking
* Pregnant less than or equal to 28 weeks gestation
* Receiving prenatal care in the District of Columbia
* Had one or more of the following risk factors: active smoking, environmental tobacco smoke exposure, depression and intimate partner violence

Exclusion Criteria:

* Non-minority race (by self report)
* Younger than 18 years of age
* Non-English speaking
* Not pregnant or pregnant greater than 28 weeks gestation
* Receiving prenatal care outside the District of Columbia
* Responded negatively to questions about risk factors
* Suicidal ideation
D: Inclusion Criteria:

* woman
* at least 18 years of age
* visiting one of the participant physicians
* in a current or recent intimate relationship during the last 12 months
* having the ability to speak and read English and give consent

Exclusion Criteria:

* visiting a provider other than the regular family physician
* new patient
* previously approached for the study
* very sick
* had a dual appointment (herself and accompanied dependent)

Answer: D
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Effect of Aging on the Isolated Pituitary Response to Gonadotropin Releasing Hormone at Baseline and With Low Dose Estrogen Administration
Brief Summary: The purpose of this study is to study the effects of aging and estrogen on the brain. Specifically, this study will examine how the hypothalamus signals the pituitary gland to secrete reproductive hormones and how that changes with aging.


Options:
A: Inclusion Criteria:

* 45-55 or 70-80 years old
* History of natural menopause defined by the absence of menses for at least 12 months (or history of surgical menopause defined as bilateral oophorectomy) and a FSH level \>26 IU/L
* On no hormonal medication or herbal supplements and/or over the counter menopause therapy for a minimum of 2 months prior to study
* Normal thyroid stimulating hormone, prolactin, factor V Leiden, and complete blood count - Normal blood urea nitrogen and creatinine (\< 2 times the upper limit of normal)
* basal metabolic index ≤ 30
* Non-smokers or smoke less than 10 cigarettes/day

Exclusion Criteria:

* Absolute contraindications to the use of physiologic replacement doses of estrogen, including a negative screening mammogram within the past 24 months
* History of coronary artery disease
* On medications thought to act centrally on the GnRH pulse generator
* Past history of hypersensitivity or allergy to narcotics, vancomycin, muscle relaxants, aspirin, and/or anaphylactic reaction(s) to other drugs
* Prior history of breast cancer and/or blood clots
B: Inclusion Criteria:

* women with recurrent implantation failure which was defined as 2-6 cycles unsuccessful of IVF-ET in which more than 10 high grade embryo were transferred

Exclusion Criteria:

* age over than 40 years old
* poor responders to ovarian stimulation
C: Inclusion Criteria:

* women who applied to our clinic due to infertility and who undergone one or more failed fresh IVF cycles previously has been included in our study for ICSI-ET (intracytoplasmic sperm injection-embryo transfer).

Exclusion Criteria:

* women with factors as hydrosalpenx, trombophilia, submucous myoma and found to have a negative impact on implantation
D: Inclusion Criteria:

Patients with an indication for IUI:

* unexplained infertility
* mild male factor infertility
* minimal-mild endometriosis

Women:

* first IUI cycle ever
* normal ovulatory cycles (26-32d)
* age\<43,BMI≤30
* presence of at least one patent tube on hysterosalpingography and/or laparoscopy
* normal uterine cavity (ultrasound, hysterosalpingography, or laparoscopy)

Men: Total motile count ≥ 5 Million/ml after capacitation

Exclusion Criteria:

* Patients with contra-indication for pregnancy , infertility or progesterone use.

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: The Efficacy of Iron Fortified Whole Maize Flour on the Iron Status of School Children in Kenya
Brief Summary: The purpose of this study is to assess whether NaFeEDTA and electrolytic iron improve iron status of young school children, when added as iron fortificants in whole maize flour.


Options:
A: Inclusion Criteria:Children:

* 3-8 years age (for the purposes of this study this will include children born within the period December 15th 1995- May 1st 2001).
* Whohave been resident in the area for 6 months or more.
* Enrolled in the selected schools
* Able to consume the target amount of porridge, at least 50% of the time during the run-in period
* Will be present in the study area for the entire study period (April - December 2004).

Exclusion Criteria:

* Children below 3 years and above 8 years of age (born after December 15th 1995 and before May 1st 2001).
* Children who have been resident in the area for less than 6 months at the time of recruitment.
* Children with obvious physical and mental disability.
* Severely malnourished children.
* Severely anaemic children (Hb \<70g/L).
B: Inclusion Criteria:

* Aged 12-59 months at the time of entry into the study
* Resident in village for at least 6-months and the caretaker plans to remain in the area for the next year
* Apparently healthy at the time of entry into the study

Exclusion Criteria:

* Severe anaemia i.e. Hb concentration \<70 g/L (See section 5.5)
* Taking iron containing haematinic supplements
* Transfused in the last six months
* Severely undernourished i.e. anthropometric indices \<-3 Z score
C: Inclusion Criteria:

* at least 18 years of age
* in first trimester of pregnancy
* plans to reside in the same village during the entire pregnancy

Exclusion Criteria:

* a minor
* not in first trimester of pregnancy
* plans to relocate during the pregnancy
D: Inclusion Criteria:

* Inclusion criteria for clusters: Each cluster will be a rural community characterized by inhabitants with low income and served by one community health center. A primary criterion is that national or other available statistics indicate a prevalence of stunting (mean length for age Z-scores in second year \< -2) of at least 20% in young children.
* Inclusion criteria for individual families:

  * Infant aged 3-4 months;
  * Primarily or exclusively breast feeding with intent to continue breast feeding through at least 1 year.

Exclusion Criteria:

* Exclusion criteria for individual families: Exclusion criteria include any population/family that is receiving or likely to receive free or subsidized complementary foods (or infant formula) through the health system or NGOs; any individual families who are feeding or intend to feed fortified infant formula or micronutrient-fortified commercial complementary foods.
* Exclusion criteria for infants: Infants meeting the following criteria will be excluded from participation:

  1. known congenital anomaly;
  2. infant of multiple births;
  3. known neurological deficit apparent at the time of enrollment (including seizures).

Answer: A
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Vaginal Cleansing at Cesarean Delivery to Reduce Infection: A Randomized, Controlled Trial
Brief Summary: The objective of the project is to find out whether cleansing the vagina before a cesarean delivery decreases the risk of complications and infections after having the baby. If this is the case, cleansing the vagina before cesarean delivery can help improve outcomes for many women and make their early postpartum recovery much more pleasant, giving a healthier start for the family.


Options:
A: Inclusion Criteria:

* Women with gestation between 34 and 41 6/7 weeks.
* Premature rupture of membranes (\> 6 hours).
* Use of prophylactic antibiotic 1 hour previous to cesarean section.

Exclusion Criteria:

* Any source of infection diagnosed previous to surgery.
* Fever of unknown origin previous to surgery.
B: Inclusion Criteria:

* Gestational age \> 37 weeks 0/7 days
* Non-emergency indication for cesarean

Exclusion Criteria:

* Urogenital tract infection within 2 weeks prior to surgery
* Chronic oral or injectable steroid use (\> 2 weeks)
* Emergency cesarean delivery
* Participation in another research study
C: Inclusion Criteria:

* Woman undergoing cesarean delivery
* At least 18 years of age

Exclusion Criteria:

* Allergy to iodine containing solutions
* Planned cesarean hysterectomy
* Prisoner
D: Inclusion Criteria:

1. Patients 18-40 years of age who will undergo cesarean deliveries.
2. Able to communicate well with the investigator \& to comply with the requirements of the entire study.
3. Verbal consent obtained from subject and husband / witness before undergoing the study entry (with the understanding that consent may be withdrawn by the patient at any time without prejudice).

Exclusion Criteria:

1. Patients with allergy to iodine containing solutions.
2. Patients with ante-partum hemorrhage.
3. Patients with ruptured membranes.
4. Patients with any known disease that increases the risk of infection e.g. immunocompromized, those receiving steroids ...etc.

Answer: C
Please select the eligibility criteria that correspond to the clinical trial below.
Title: Swiss Interventional Study on Silent Ischemia (SWISSI 2)
Brief Summary: Silent ischemia has been shown to negatively affect prognosis in patients after myocardial infarction. However, long-term outcome data in totally asymptomatic patients is missing and it is unknown whether angioplasty in addition to secondary preventive measures is superior to antiischemic drug therapy in these patients. Therefore, the SWISSI 2 study was started 15 years ago with the aim of comparing the effects of angioplasty with medical therapy on long-term outcome in patients with recent myocardial infarction and silent ischemia.


Options:
A: Inclusion Criteria:

* Enrolled in a Durham VA Primary Care Clinic for at least one year
* Age ≥ 55 years old
* Diagnosis ICD 401.0, 401.1, or 401.9 on outpatient electronic encounter forms in the prior year
* Received a prescription for hypertensive medication (ACE inhibitors, beta blockers, calcium channel blockers, diuretics, alpha1 blockers, and/or central alpha2 agonists) in the previous year
* Inadequate BP control based on an average of prior 12-month clinic BP measurements
* Have a baseline EKG within the last 5 years to evaluate the presence of left ventricular hypertrophy.

Exclusion Criteria:

* Hospitalized at the DVAMC for a myocardial infarction (MI), coronary artery revascularization, or diagnosis of metastatic cancer in the past 6 months
* Prior history of stroke
* Active diagnosis of psychosis or dementia documented in medical record
* Participating in another chronic disease self-management study
* Resident of a nursing home
* Does not have access to a telephone
* Refusal to provide informed consent
B: Inclusion Criteria:

* Recent myocardial infarction within last 3 months
* Documented silent myocardial ischemia (type I)

Exclusion Criteria:

* Symptomatic myocardial ischemia
C: Inclusion Criteria:

* Adults (\>= 18 years)
* made an office visit to a primary care physician (PCP) at Revere Health Center in the year prior to May 2009
* has a telephone
* listed as a smoker in the past 5 years in the electronic health record

Exclusion Criteria:

* severe psychiatric or neurologic diagnosis (e.g., psychosis, dementia) on problem list of electronic health record
D: Inclusion Criteria:

* age 50 and older
* prescription for at least one cardiovascular medication for heart failure
* plan to receive care and prescriptions at the study health care facility
* ability to hear within the normal range of conversation
* English speaking
* willingness to obtain echocardiography

Exclusion Criteria:

* dementia

Answer: B